Genetic Causes of Intellectual Disability: Down, Fragile X, Rett Syndromes
Intellectual disability (ID) has diverse genetic etiologies. Three major syndromes illustrate different genetic mechanisms: chromosomal, single-gene X-linked, and X-linked dominant.
Chromosomal: Down Syndrome
Trisomy 21 (extra chromosome 21) → overexpression of ~300 genes → characteristic phenotype (intellectual disability, hypotonia, congenital heart defects, distinct facial features, increased leukemia risk). Most common genetic cause of ID (~1/700 births).
Single-Gene X-Linked: Fragile X Syndrome
Most common inherited cause of ID. CGG repeat expansion (>200 repeats, full mutation) in the FMR1 gene (Xq27.3) → methylation and transcriptional silencing → loss of FMRP (fragile X mental retardation protein) → dysregulated synaptic plasticity. X-linked dominant with variable expressivity; males typically more severely affected.
X-Linked Dominant: Rett Syndrome
MECP2 mutations (Xq28) → severe ID, developmental regression (6–18 months), hand stereotypies (hand-wringing), seizures, autonomic dysfunction, autism features. Almost exclusively females (lethal in most males).
Other Notable Single-Gene ID Syndromes
- Angelman syndrome: Maternal 15q11-q13 deletion or UBE3A mutation → severe ID, happy demeanor, ataxia, seizures, absent speech.
- Prader-Willi syndrome: Paternal 15q11-q13 deletion → neonatal hypotonia, hyperphagia/obesity, hypogonadism, mild-moderate ID.
- Rubinstein-Taybi syndrome: CREBBP or EP300 mutations → ID, broad thumbs/toes, characteristic facies.
Diagnostic Approach
- Chromosomal microarray (CMA): First-tier for global developmental delay/ID—detects CNVs.
- Fragile X testing (PCR/Southern blot): Recommended for all males with unexplained ID; females with family history or clinical features.
- Exome/genome sequencing: For nondiagnostic CMA/Fragile X; identifies single-gene disorders.
- Targeted panels: For specific phenotypes (e.g., RASopathies, neurodevelopmental disorders).
Genetic diagnosis guides prognosis, recurrence risk counseling, syndrome-specific surveillance (e.g., cardiac in Down, seizure monitoring in Angelman), and access to targeted therapies/clinical trials.
Genetic Disorders - Related Articles
- Genetics and Muscle Growth: How DNA Sets the Framework for Hypertrophy
- Understanding and Managing Angelman Syndrome: A Comprehensive Guide
- Genetic Disease Screening: Understanding Risks and Options
- STDs: Causes, Transmission, and Prevention Essentials
- Understanding DNA Testing for Down Syndrome: Early Detection & Accuracy
- Understanding Sickle Cell Disease and Pain Management
- Understanding & Caring for Clubfoot Braces: A Parent's Guide
